Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,466 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01612988 | Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL(BOMP) | terminated | Phase 2 | 74 | French Innovative Leukemia OrganisationOTHER | 1 | Apr 27, 2018 | clinicaltrials |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | terminated | Phase 1 / Phase 2 | 8 | Milton S. Hershey Medical CenterOTHER | 1 | Apr 25, 2018 |
| NCT01382615 | Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research | terminated | — | 29 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02732925 | To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma(MELODY) | terminated | N/A | 2 | Royal National Orthopaedic Hospital NHS TrustOTHER | 1 | Apr 6, 2018 | clinicaltrials |
| NCT00909948 | Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant(RLI) | terminated | Phase 1 | 7 | Massachusetts General HospitalOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status | terminated | Phase 4 | 89 | Hoffmann-La RocheINDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
| NCT02488512 | Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas(itTRIOlym) | terminated | Phase 2 | 1 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT02530125 | Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission | terminated | Phase 2 | 4 | Northwestern UniversityOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT00113646 | Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies | terminated | Phase 2 | 14 | Massachusetts General HospitalOTHER | 1 | Mar 16, 2018 | clinicaltrials |
| NCT00113828 | Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies | terminated | Phase 2 | 5 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT02366663 | BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL(SPINOZA) | terminated | Phase 3 | 3 | City of Hope Medical CenterOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT01313611 | BRIEF Bendamustine and Rituximab In Elderly Follicular(BRIEF) | terminated | Phase 2 | 62 | The Lymphoma Academic Research OrganisationOTHER | 2 | Mar 7, 2018 | clinicaltrials |
| NCT02137889 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients(VAY736Y) | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 2 | Feb 28, 2018 | clinicaltrials |
| NCT01147393 | Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT01002248 | Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | terminated | Phase 3 | 135 | AEterna ZentarisINDUSTRY | 9 | Feb 9, 2018 | clinicaltrials |
| NCT01315873 | Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma | terminated | Phase 2 | 24 | NYU Langone HealthOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT01675141 | Lenalidomide Maintenance Therapy for Multiple Myeloma | terminated | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01446900 | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma | terminated | Phase 2 | 25 | European Institute of OncologyOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02983097 | Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP(R²-DHAP) | terminated | Phase 1 / Phase 2 | 34 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00455897 | CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 3 | Massachusetts General HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02200848 | Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 1 | 5 | Georgetown UniversityOTHER | 1 | Jan 12, 2018 | clinicaltrials |
| NCT00562965 | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 3 | 29 | PfizerINDUSTRY | 14 | Jan 9, 2018 | clinicaltrials |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00963872 | Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer | terminated | Phase 1 / Phase 2 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00772668 | Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL | terminated | N/A | 3 | University of MiamiOTHER | 1 | Dec 11, 2017 | clinicaltrials |
| NCT01343368 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | terminated | Phase 2 | 19 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01518465 | Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma | terminated | Phase 2 | 13 | University of Southern CaliforniaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01969565 | Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma | terminated | Phase 2 | 1 | Emory UniversityOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00574080 | UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide | terminated | Phase 3 | 20 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00657553 | Preemptive Strike With Bortezomib in Multiple Myeloma Patients(2007-77) | terminated | Phase 3 | 10 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02700022 | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas | terminated | Phase 1 | 1 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02815397 | DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma(DLBCL) | terminated | Phase 2 | 2 | Rush University Medical CenterOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00113919 | UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients | terminated | Phase 1 / Phase 2 | 14 | University of ArkansasOTHER | 1 | Oct 16, 2017 | clinicaltrials |
| NCT01646762 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Oct 16, 2017 | clinicaltrials |
| NCT02455297 | Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) | terminated | Phase 2 | 4 | BayerINDUSTRY | 1 | Oct 2, 2017 | clinicaltrials |
| NCT00849251 | Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 31 | University of WashingtonOTHER | 1 | Sep 8, 2017 | clinicaltrials |
| NCT00857324 | Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients | terminated | Phase 1 / Phase 2 | 18 | Tiziana MarangonOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT01720043 | Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients | terminated | Phase 2 | 8 | University of UtahOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT00714259 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies | terminated | Phase 2 / Phase 3 | 5 | University of Alabama at BirminghamOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT00837200 | Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies | terminated | Phase 2 | 13 | Milton S. Hershey Medical CenterOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT00843310 | Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma | terminated | Phase 2 | 8 | NYU Langone HealthOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00587457 | A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia | terminated | Phase 1 | 11 | MedImmune LLCINDUSTRY | 2 | Jul 6, 2017 | clinicaltrials |
| NCT00496132 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 16 | Genentech, Inc.INDUSTRY | 0 | Jul 2, 2017 | clinicaltrials |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | N/A | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT01251952 | Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation | terminated | Phase 1 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT01548573 | Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | terminated | Phase 2 | 19 | University of IowaOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01965834 | Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma | terminated | Phase 2 | 6 | University of MiamiOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT02619812 | Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT | terminated | Phase 2 | 4 | Mayo ClinicOTHER | 1 | Jun 14, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Apr 27, 2018source: clinicaltrials